PDCD1 and cancer: Interfering with immune checkpoints signaling [e.g., through the modulation of programmed cell death 1 (PD-1) and its ligand (PD-L1)] represents an alternative treatment strategy for several cancers and is currently being employed in combination with chemotherapy as a neoadjuvant or adjuvant treatment (5–8).